Zhongke-Jiayi New Patent Probiotics- Mixed Strains for Preventing Helicobacter pylori Infection

Helicobacter pylori, which often parasitizes in gastric mucosal tissue, mainly causes chronic gastritis and peptic ulcers after infection. It is closely related to diseases such as gastric cancer, gastric mucosa associated lymphoid tissue (MALT) lymphoma, and is listed as a Class I biological carcinogen by the World Health Organization (WHO). The average infection rate of Helicobacter pylori in China is around 50%.

Helicobacter pylori is highly contagious and generally spreads through the digestive tract, with unhygienic eating habits being the main mode of transmission. Most Helicobacter pylori infected individuals have no obvious symptoms in the early stages of infection, and long-term infection may lead to chronic gastritis, peptic ulcers, and other conditions. Therefore, it is very important to take preventive measures in daily life.

There are currently many methods for treating Helicobacter pylori infection, such as triple therapy, quadruple therapy, or the use of bismuth nitrate suspension. However, these products are mostly targeted at the gastrointestinal tract that has been infected with Helicobacter pylori, with complex ingredients and strong drug properties, and are not suitable for the daily prevention of Helicobacter pylori in healthy gastrointestinal tract.

In response to the technical problem that the existing products for treating Helicobacter pylori infection have complex ingredients, strong drug properties, and are not suitable for daily prevention of Helicobacter pylori, the present invention provides a composite bacterial agent for preventing Helicobacter pylori infection and its preparation method and application, with mild and safe ingredients.

The present invention provides a composite microbial agent for preventing Helicobacter pylori infection, including Lactobacillus reuteri JYLB-291 with preservation number CGMCC No.18041 and Lactobacillus casei L. casei 21with preservation number CGMCCNo.21373  and Lactobacillus acidophilus JYLA-191 with preservation number CGMCCNo.21371.

In the composite microbial agent provided by the present invention for preventing Helicobacter pylori infection, Lactobacillus casei L Casei 21 and Lactobacillus Reuteri JYLB-291 have good antibacterial and anti-inflammatory functions, while Lactobacillus acidophilus JYLA-191 has strong gastrointestinal fluid survival ability. The three strains are combined to complement each other and synergistically enhance efficiency. Through experimental verification, this composite microbial agent can significantly reduce the infection rate of Helicobacter pylori, improve the immunity of healthy individuals to Helicobacter pylori, and help prevent Helicobacter pylori infection in healthy individuals; Moreover, this composite bacterial agent can maintain the balance of inflammatory cells, inhibit gastric inflammation, and reduce the infectivity of Helicobacter pylori infected individuals.